|Table of Contents|

Construction and validation of a nomogram model of mediastinal lymph node metastasis in non-small cell lung cancer based on MSCT perfusion parameters

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 22
Page:
4206-4211
Research Field:
Publishing date:

Info

Title:
Construction and validation of a nomogram model of mediastinal lymph node metastasis in non-small cell lung cancer based on MSCT perfusion parameters
Author(s):
WANG Dong1; XU Fenglin2; YU Xiaohan1; GAI Xue1; HAO Chunxiao1; ZHAO Liqun1
1.The First Affiliated Hospital of Qiqihar Medical College,Heilongjiang Qiqihar 161000,China;2.Pathological Center of Qiqihar Medical College,Heilongjiang Qiqihar 161000,China.
Keywords:
non-small cell lung cancer; mediastinal lymph node metastasis; MSCT perfusion imaging; quantitative parameters
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.22.020
Abstract:
Objective:To investigate the predictive value of constructing a nomogram model to predict mediastinal lymph node metastasis in non-small cell lung cancer (NSCLC) based on multi-slice CT (MSCT) perfusion parameters.Methods:380 patients with NSCLC in our hospital from January 2010 to January 2020 were included as the modeling group,including 159 patients with mediastinal lymph node metastasis and 221 patients without metastasis.Another 120 patients with NSCLC were selected from February 2020 to February 2023 in a multicenter as the validation group.The clinical data and MSCT perfusion parameters of the two groups were compared,and Logistic regression analysis was used to screen the factors influencing mediastinal lymph node metastasis in NSCLC and construct a nomogram model.The consistency and diagnostic efficacy of this model were analyzed by calibration curves and receiver operating characteristic (ROC) curves,and external validation was performed.Results:Logistic regression analysis showed that the type of pathology (OR=0.730,95%CI=0.567~0.941),tumor diameter (OR=12.195,95%CI=3.145~47.289),short diameter of mediastinal lymph nodes ipsilateral to the tumor (OR=14.125,95%CI=2.857~69.832),serum carcinoembryonic antigen (CEA) (OR=9.814,95%CI=2.415~39.882),blood flow (BF) in the lesion area (OR=11.348,95%CI=3.074~41.892),blood volume (BV) (OR=11.456,95%CI=2.895~45.337),mean transit time (MTT) (OR=0.456,95%CI=0.274~0.759),and permeability surface (PS) (OR=10.475,95%CI=2.419~45.363) were independent factors influencing mediastinal lymph node metastasis in NSCLC patients (P<0.05).The C-index of the model was 0.921 and 0.918 in the modeling group and the validation group,respectively.The calibration curve showed that the nomogran model predicted the risk of mediastinal lymph node metastasis in the modeling group and the validation group with good discrimination and accuracy.The area under the curve (AUC) was 0.956 (95%CI=0.942~0.978) in the modeling group and 0.950 (95%CI=0.934~0.991) in the validation group,when the ROC curve was applied to analyze the efficiency of nomogram model in predicting the risk of mediastinal lymph node metastasis in NSCLC patients in the modeling group and the validation group.Conclusion:The nomogram model of mediastinal lymph node metastasis in NSCLC was constructed based on MSCT perfusion parameters with good discrimination and calibration,which can achieve individualized assessment of mediastinal lymph node metastasis in NSCLC patients.

References:

[1] ALESANDER M,KIM SY,CHENG H.Update 2020:Management of non-small cell lung cancer［J］.Lung,2020,198(6):897-907.
[2] OUDKERK M,LIU S,HEUVELMANS MA,et al.Lung cancer LDCT screening and mortality reduction - evidence,pitfalls and future perspectives［J］.Nat Rev Clin Oncol,2021,18(3):135-151.
[3] JASPER K,STILES B,MCDONALD F,et al.Practical management of oligometastatic non-small-cell lung cancer［J］.J Clin Oncol,2022,40(6):635-641.
[4] MITHOOWANI H,FEBBRARO M.Non-small-cell lung cancer in 2022:A review for general practitioners in oncology［J］.Curr Oncol,2022,29(3):1828-1839.
[5] 许颍,李广利,张申,等.18F-FDG PET/CT代谢参数在预测非小细胞肺癌患者纵隔淋巴结转移中的临床价值［J］.国际放射医学核医学杂志,2021,45(8):495-500. XU Y,LI GL,ZHANG S,et al.The clinical value of 18F-FDG PET/CT metabolic parameters in predicting mediastinal lymph node metastasis in patients with non-small cell lung cancer［J］.International Journal of Radiomedicine Nuclear Medicine,2021,45 (8):495-500.
[6] 王玉成,陈小宇.64排CT扫描结合血清学检查在非小细胞性肺癌纵隔淋巴结转移诊断中的应用效果［J］.影像研究与医学应用,2022,6(14):53-55. WANG YC,CHEN XY.The application effect of 64 row CT scan combined with serological examination in the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer［J］.Imaging Research and Medical Application,2022,6(14):53-55.
[7] 孙国臣,王明甫.低剂量CT灌注联合影像组学评估非小细胞肺癌的纵隔淋巴转移［J］.放射学实践,2021,36(2):186-193. SUN GC,WANG MF.Evaluation of mediastinal lymph node metastasis in non-small cell lung cancer using low-dose CT perfusion combined with imaging omics［J］.Radiological Practice,2021,36(2):186-193.
[8] ZHOU YJ,SIMAJ,LI QY,et al.Risk factors and nomogram model establishment for incision infection in patients with bladder cancer after radical resection［J］.Asian J Surg,2022,S1015-9584(22):1276-1283.
[9] ZHANG HR,ZHAO YL,WANG F,et al.Establishment and validation of a nomogram model for periprosthetic infection after megaprosthetic replacement around the knee following bone tumor resection:A retrospective analysis［J］.Orthop Traumatol Surg Res,2020,106(3):421-427.
[10] 林志强.非小细胞肺癌纵隔淋巴结转移风险模型的构建及预测效能的初步验证［J］.现代肿瘤医学,2021,29(8):1328-1331. LIN ZQ.Construction of a risk model for mediastinal lymph node metastasis in non-small cell lung cancer and preliminary validation of its predictive efficacy［J］.Modern Oncology,2021,29(8):1328-1331.
[11] JIN J,XU Y,HU X,et al.Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer［J］.Curr Oncol,2020,27(3):e283-e293.
[12] WHITE AA,LEE DN,MZZOLA E,et al.Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer［J］.J Surg Oncol,2021,123(2):579-586.
[13] LE X,NILSSON M,GOLDMAN J,et al.Dual EGFR-VEGF pathway inhibition:a promising strategy for patients with EGFR-mutant NSCLC［J］.J Thorac Oncol,2021,16(2):205-215.
[14] WANG M,LI Y,XIAO Y,et al.Nicotine-mediated OTUD3 downregulation inhibits VEGF-C mRNA decay to promote lymphatic metastasis of human esophageal cancer［J］.Nat Commun,2021,12(1):7006.
[15] LI X,SONG D,LIU H,et al.Expression levels of VEGF-C and VEGFR-3 in renal cell carcinoma and their association with lymph node metastasis［J］.Exp Ther Med,2021,21(6):554.
[16] ZHENG H,CHEN C,LUO Y,et al.Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer［J］.Clin Transl Med,2021,11(7):e497.
[17] ZHONG W,GUO X,HE Y,et al.Association between single nucleotide polymorphisms of VEGF gene and pelvic lymph node metastasis in patients with early-stage cervical cancer［J］.J Obstet Gynaecol,2022,42(5):1347-1351.
[18] 张玉婷,姜永宏,马荣泽,等.颈部淋巴结CT灌注成像与微血管密度的研究［J］.实用放射学杂志,2020,36(4):546-549. ZHANG YT,JIANG YH,MA RZ,et al.Study on CT perfusion imaging and microvascular density of cervical lymph nodes［J］.Journal of Practical Radiology,2020,36(4):546-549.
[19] 高鹏飞,李娜,景引军.肝癌患者CT灌注成像参数与黏蛋白1、存活蛋白及微血管密度的关系［J］.癌症进展,2022,20(2):148-150,173. GAO PF,LI N,JING YJ.The relationship between CT perfusion imaging parameters and mucin 1,survival protein,and microvessel density in liver cancer patients［J］.Cancer Progress,2022,20(2):148-150,173.
[20] 潘颖奇,陈婷.CT灌注成像评估NSCLC患者放化疗疗效价值探究［J］.中国CT和MRI杂志,2021,19(11):59-61. PAN YQ,CHEN T.Exploration of the value of CT perfusion imaging in evaluating the efficacy of radiotherapy and chemotherapy in NSCLC patients［J］.Chin Journal of CT and MRI,2021,19(11):59-61.
[21] 石宏哲,王海霞,秦铮,等.MSCT灌注成像参数在重症急性胰腺炎临床诊治中的应用价值［J］.中国CT和MRI杂志,2022,20(4):112-114. SHI HZ,WANG HX,QIN Z,et al.The application value of MSCT perfusion imaging parameters in the clinical diagnosis and treatment of severe acute pancreatitis［J］.Chinese Journal of CT and MRI,2022，20(4):112-114.

Memo

Memo:
黑龙江省齐齐哈尔市科技计划联合引导项目（编号：LSFGG-2022074）
Last Update: 1900-01-01